[Clinical studies of T-1982 (cefbuperazone) in the field of pediatrics].
T-1982 (cefbuperazone), a new cephamycin antibiotic, was clinically and bacteriologically studied in 25 children with bacterial infections. The following results were obtained. 1. The antibacterial activity of T-1982 was determined against clinically isolated bacteria. T-1982 demonstrated excellent activity against Gram-negative bacilli, the MICs being less than 0.39 microgram/ml against E. coli and K. oxytoca, less than 1.56 microgram/ml against H. influenzae. 2. Clinical response was excellent or good in all 24 cases evaluated. The efficacy rate was 100%. 3. As for side effects associated with T-1982, slight and transient elevation of GOT, GPT and eosinophil, slight decrease of platelet and eruption were observed. From these results, T-1982 is considered to be a useful antibiotic for treating bacterial infections in children.
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007223:Infant; D008297:Male; D011014:Pneumonia / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; C035978:cefbuperazone